Danai Dima

Fred Hutch Cancer Center, University of Washington, Cleveland Clinic

Danai Dima's recent research contributions have significantly advanced the field of multiple myeloma treatment. Studies such as "time is nephron" and "impact of frailty on outcomes after CAR-T cell therapy for patients with relapsed/refractory multiple myeloma" highlight the importance of timely transplantation and considering patient frailty in CAR-T cell therapy decision-making. Other research, including "development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma" and "safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma," has improved understanding of CAR-T cell therapy outcomes. Additionally, research on novel immunotherapies like idecabtagene vicleucel (ide-cel) and teclistamab has shown promising results in treating multiple myeloma patients with varying levels of disease progression. These findings have the potential to improve treatment strategies and patient outcomes for individuals with this complex cancer type.